|
1
|
Glazer CH, Bonde JP, Eisenberg ML,
Giwercman A, Hærvig KK, Rimborg S, Vassard D, Pinborg A, Schmidt L
and Bräuner EV: Male infertility and risk of nonmalignant chronic
diseases: A systematic review of the epidemiological evidence.
Semin Reprod Med. 35:282–290. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bridges N, Trofimenko V, Fields S, Carrell
D, Aston K and Hotaling J: Male factor infertility and clomiphene
citrate: A meta-analysis - the effect of clomiphene citrate on
oligospermia. Urol Pract. 2:199–205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chirputkar R and Vaidya A: Understanding
infertility and the potential role of stem cells in infertility
treatment: A short communication. Int J Reprod Fertil Sex Health.
1:37–40. 2015.
|
|
4
|
Sami MA, Nazar H and Usmanghani K:
Idiopathic oligospermia treatment: An alternate approach. Int J Med
Med Sci. 7:74–79. 2015. View Article : Google Scholar
|
|
5
|
Hezelgrave N, Abbott D and Shennan AH:
Pre-implantation genetic diagnosis in oligozoospermiaChallenging
Concepts Obstet Gynaecol. Oxford University Press; Oxford: pp.
49–59. 2014
|
|
6
|
Legro RS, Brzyski RG, Diamond MP,
Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q,
Alvero R, et al: NICHD reproductive medicine network: Letrozole
versus clomiphene for infertility in the polycystic ovary syndrome.
N Engl J Med. 371:119–129. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
André F, Stemmer SM, Hortobagyi GN, Burris
HA, Paluch-Shimon S, Campone M, Villanueva C, Chan A, Wist E,
Marschner N, et al: Ribociclib + letrozole for first-line treatment
of HR+, HER2− ABC: Efficacy, safety, and
pharmacokinetics. Eur J Cancer. 69:S72016. View Article : Google Scholar
|
|
8
|
Diamond MP, Legro RS, Coutifaris C, Alvero
R, Robinson RD, Casson P, Christman GM, Ager J, Huang H, Hansen KR,
et al: NICHD Reproductive Medicine Network: Coutifaris. Letrozole,
gonadotropin, or clomiphene for unexplained infertility. N Engl J
Med. 373:1230–1240. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Milardi D, Luca G, Grande G, Ghezzi M,
Caretta N, Brusco G, De Filpo G, Marana R, Pontecorvi A, Calafiore
R, et al: Prednisone treatment in infertile patients with
oligozoospermia and accessory gland inflammatory alterations.
Andrology. 5:268–273. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nozawa YI, Yao E, Gacayan R, Xu SM and
Chuang PT: Mammalian Fused is essential for sperm head shaping and
periaxonemal structure formation during spermatogenesis. Dev Biol.
388:170–180. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu Y, Wang N, Yu Y, Li Y, Li YB, Yu YB,
Zhou XQ and Sun ZW: Exposure to silica nanoparticles causes
reversible damage of the spermatogenic process in mice. PLoS One.
9:e1015722014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Finn RS, Crown JP, Lang I, Boer K,
Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et
al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in
combination with letrozole versus letrozole alone as first-line
treatment of oestrogen receptor-positive, HER2-negative, advanced
breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study.
Lancet Oncol. 16:25–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Finn RS, Martin M, Rugo HS, Jones S, Im
SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, et al:
Palbociclib and letrozole in advanced breast cancer. N Engl J Med.
375:1925–1936. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dickler MN, Barry WT, Cirrincione CT,
Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE,
Hahn O, et al: Phase III trial evaluating letrozole as first-line
endocrine therapy with or without bevacizumab for the treatment of
postmenopausal women with hormone receptor-positive advanced-stage
breast cancer: CALGB 40503 (Alliance). J Clin Oncol. 34:2602–2609.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Noorafshan A, Ahmadi M, Mesbah SF and
Karbalay-Doust S: Stereological study of the effects of letrozole
and estradiol valerate treatment on the ovary of rats. Clin Exp
Reprod Med. 40:115–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Simoni M, Santi D, Negri L, Hoffmann I,
Muratori M, Baldi E, Cambi M, Marcou M, Greither T, Baraldi E, et
al: Treatment with human, recombinant FSH improves sperm DNA
fragmentation in idiopathic infertile men depending on the FSH
receptor polymorphism p.N680S: A pharmacogenetic study. Hum Reprod.
31:1960–1969. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bernet JD, Doles JD, Hall JK, Tanaka Kelly
K, Carter TA and Olwin BB: p38 MAPK signaling underlies a
cell-autonomous loss of stem cell self-renewal in skeletal muscle
of aged mice. Nat Med. 20:265–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Loi S, Dushyanthen S, Beavis PA, Salgado
R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV,
et al: RAS/MAPK activation is associated with reduced
tumor-infiltrating lymphocytes in triple-negative breast cancer:
Therapeutic cooperation between MEK and PD-1/PD-L1 immune
checkpoint inhibitors. Clin Cancer Res. 22:1499–1509. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jaldety Y and Breitbart H: ERK1/2 mediates
sperm acrosome reaction through elevation of intracellular calcium
concentration. Zygote. 23:652–661. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu X, Tang Z, Li Y, Liu W, Zhang S, Wang
B, Tian Y, Zhao Y, Ran H, Liu W, et al: Deletion of the tyrosine
phosphatase Shp2 in Sertoli cells causes infertility in mice. Sci
Rep. 5:129822015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tögel L, Nightingale R, Chueh AC,
Jayachandran A, Tran H, Phesse T, Wu R, Sieber OM, Arango D,
Dhillon AS, et al: Dual targeting of bromodomain and extraterminal
domain proteins, and WNT or MAPK signaling, inhibits c-MYC
expression and proliferation of colorectal cancer cells. Mol Cancer
Ther. 15:1217–1226. 2016. View Article : Google Scholar : PubMed/NCBI
|
